

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	09/109,045
		Filing Date	November 12, 2000
		First Named Inventor	M. Rignon Lentz
		Group Art Unit	
		Examiner Name	
Sheet 1 of 3	Attorney Docket Number	LEN 102	

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	US Patent Document		Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
JS		4,708,713		Lentz	11-24-1987	
		5,135,919		Folkman et al.	08-04-1992	
		5,147,638		Esmon et al.	09-15-1992	
		5,290,807		Folkman et al.	03-01-1994	
		5,629,327		D'Amato	05-13-1997	
		5,639,725		O'Reilly et al.	06-17-1997	
		5,698,586		Kishimoto et al.	12-16-1997	
		5,712,291		D'Amato	06-27-1998	
		5,713,491		Hughes et al.	02-03-1998	
		5,716,981		Hunter et al.	02-10-1998	
		5,733,876		O'Reilly et al.	03-31-1998	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>8</sup>
		Office. <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				

Examine Signature	G. Schuyler	Date Considered	10/2/02
-------------------	-------------	-----------------	---------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>8</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	09/709,045
		Filing Date	November 12, 2000
		First Named Inventor	M. Rignon Lentz
		Group Art Unit	1647
		Examiner Name	J. Seharviseyon
Sheet 2 of 3	Attorney Docket Number	LEN 102	

## OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
JS		ANDREWS, et al., "Characterization of the receptor for tumor necrosis factor (TNF) and lymphotoxin LT on human T lymphocytes: TNF and LT differ in their receptor binding properties and the induction of MHC class I proteins on a human CD4+ T cell hybridoma," <i>J Immunol</i> 144:2582-2591 (1990).	✓
		CHEN, et al., "Soluble TNF-α receptors are constitutively shed and downregulate adhesion molecule expression in malignant gliomas," <i>J. Neuropathol. Exp. Neurol.</i> 56(5):541-550 (1997).	✓
		CLACKSON, et al., "Making antibody fragments using phage display libraries," <i>Nature</i> 352:624-688 (1991).	✓
		DAUGHERTY, et al., "Polymerase chain reaction facilitates the cloning, CDR-grafting, and rapid expression of a murine monoclonal antibody directed against the CD18 component of leukocyte integrins," <i>Nucl. Acids Res.</i> 19:2471-2476 (1991).	✓
		EY, et al., "Isolation of pure IgG <sub>1</sub> , IgG <sub>2a</sub> , and IgG <sub>2b</sub> immunoglobulins from mouse serum using protein A-Sepharose," <i>Immunochemistry</i> 15:429-436 (1978).	✓
		FEINMAN, et al., "Tumor necrosis factor is a important mediator of tumor cell killing by human monocytes," <i>J Immunol</i> 138:635 (1987).	✓
		GATANAGA, et al., "Identification of TNF-LT blocking factor(s) in the serum and ultrafiltrates of human cancer patients," <i>Lymphokine Res</i> 9:225-9 (1990).	✓
		HARANAKA, et al, "Cytotoxic activity of tumor necrosis factor (TNF) on human cancer cells in vitro," <i>Jpn J Exp Med</i> 51:191 (1981).	✓
	<u>Hemostasis and Thrombosis: Basic Principles and Clinical Practice</u> 2nd Ed., Colman, R.W., et al., p. 263 (J.B.Lippincott, Philadelphia, PA 1987).	✓	
	HOWARD, et al., "Vaccinia virus homologues of the Shope fibroma virus inverted terminal repeat proteins and a discontinuous ORF related to the tumor necrosis factor receptor family," <i>Virology</i> 180:633-664 (1991).	✓	

Examiner's Signature	<i>gze</i>	Date Considered	10/2/02
----------------------	------------	-----------------	---------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	09/709,045
				Filing Date	November 12, 2000
				First Named Inventor	M. Rignon Lentz
				Group Art Unit	1647
				Examiner Name	J. Schavalevich
Sheet	3	of	3	Attorney Docket Number	LEN 102

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
/CMW/		JABLONSKA & PEITRUSKA, "Release of soluble tumor necrosis factor receptors from polymorphonuclear cells of breast cancer patients," <i>Arch. Immunol. Ther. Exp.</i> (Warsz) 45(5-6)449-453 (1997).	/
		KABAT, et al., <u>Sequences of Proteins of Immunological Interest</u> 4 <sup>th</sup> Ed. (U.S. Dept. Health and Human Services, Bethesda, MD, 1987).	/
		LANGKOPF, et al., "Soluble tumor necrosis factor receptors as prognostic factors in cancer patients," <i>Lancet</i> 344:57-58 (1994).	/
		MATHIAS, et al., "Activation of the Sphingomyelin signaling pathway intact EL4 cells and in a cell-free system by IL-1b," <i>Science</i> 259:519-522 (1993).	/
		MATSCHINER, et al., <u>Current Advances in Vitamin K Research</u> , pp. 135-140, John W. Suttie, ed. (Elsevier Science Publishing Co., Inc. 1988).	/
		OLD, Antitumor activity of microbial products and tumor necrosis factor, and Bonavida B, et al., (eds): <u>Tumor Necrosis Factor/Cachecin and Related Cytokines</u> , Basell, Karger, p7 (1988).	/
		PHILIP, et al., "Tumor necrosis factor as immunomodulator and mediator of monocyte cytotoxicity induced by itself, Gamma-interferon and Interleukin-1," <i>Nature</i> 323:86 (1986).	/
		URBAN, et al., "Tumor necrosis factor: A potent effector molecule for tumor cell killing by activated macrophages," <i>Proc Natl Acad Sci USA</i> 83:5233 (1986).	/
/CMW/		ZIEGLER-HEITBROCK, et al., "Tumor necrosis factor as effector molecule in monocyte-mediated cytotoxicity," <i>Cancer Res</i> 46:5947 (1986).	/

Examiner's Signature	<i>G. J. [Signature]</i>	Date Considered	10/2/02
----------------------	--------------------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

47

Substitute for form 1449A/PTO

FEB 26 2002

(use as many sheets as necessary)

**COPY OF PAPERS  
ORIGINALLY FILED**

Sheet

1

of

2

Application Number

09/709,045

**Filing Date**

November 10, 2000

**First Named Inventor**

M. Riadon Lentz

### Group Art Unit

1647

Examiner Name

J. Seharaseyon

Attorney Docket Number

LEN 102

[illegible]

RECEIVED

MAR - 4 2002

TECH CENTER 1600/2900

[illegible]

**Examine  
Signature**

Geel


Date Considered
-----------------

PO 1102

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.



Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

COPY OF PAPERS  
ORIGINALLY FILED

Complete if Known

RECEIVED

MAR - 4 2002

TECH CENTER 1600/2900

Application Number

09/709,045

Filing Date

November 10, 2000

First Named Inventor

M. Rigdon Lentz

Group Art Unit

1647

Examiner Name

J. Sevovaseyon

Attorney Docket Number

LEN 102

Sheet

2

of

2

### OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
JS		GATANAGA, et al., "Purification and characterization of an inhibitor (soluble tumor necrosis factor receptor) for tumor necrosis factor and lymphotoxin obtained from the serum ultrafiltrates of human cancer patients," <i>Proceedings of the National Academy of the USA</i> 87(22):8781-87814 (1990).	✓
		LENTZ, "Continuous whole blood UltraPheresis procedure in patients with metastatic cancer," <i>Journal of Biological Response Modifiers</i> 8(5):511-527 (1989).	✓
		LENTZ, "The role of therapeutic apheresis in the treatment of cancer: a review," <i>Therapeutic Apheresis</i> 3(1):40-49 (1999).	✓
		SELINSKY, et al., "Multifaceted inhibition of anti-tumor immune mechanisms by soluble tumour necrosis factor receptor type-1," <i>Immunology</i> 94(1):88-93 (1998).	✓
		TETTA, et al., "Continuous plasma filtration coupled with sorbents," <i>Kidney International</i> 53(66):S186-S189 (1998).	✓

Examiner's  
Signature

*[Signature]*

Date Considered

10/1/02

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

